New research from the Human Microbiology Institute has shown that many diseases, from Alzheimer’s to cancer and others, could be linked to bacterial viruses, a…

MD Anderson scientists have pinpointed how melanoma tumors resist the cancer drug ipilimumab: genetic mutations in an immune pathway.

Shares in tiny Galectin Therapeutics fell 50% in after-hours trading on the back of data from a Phase IIa nonalcoholic steatohepatitis trial.

Researchers from Washington University in St. Louis have prevented cartilage degeneration in mice by injecting their injured joints with nanoparticles.

Shire has returned rights to the two biosimilars that Baxalta had in development.

Galapagos CEO Onno van de Stolpe has confirmed that the standstill agreement stopping Gilead from increasing its stake in his company is still active.

The Cambridge, MA-based company is ready to graduate from a venture-oriented CEO to a former pharma exec ready to jump into the clinical fray.

Boston Scientific has agreed to acquire EndoChoice for approximately $210 million in a deal that will see the latter folding into Boston Sci’s endoscopy…

Startup Fortis has emerged from stealth mode with an $18 million Series A financing led by Avalon Ventures.